Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.

Authors: Weinhold, N  Johnson, DC  Chubb, D  Chen, B  Forsti, A  Hosking, FJ  Broderick, P  Ma, YP  Dobbins, SE  Hose, D  Walker, BA  Davies, FE  Kaiser, MF  Li, NL  Gregory, WA  Jackson, GH  Witzens-Harig, M  Neben, K  Hoffmann, P  Nothen, MM  Muhleisen, TW  Eisele, L  Ross, FM  Jauch, A  Goldschmidt, H  Houlston, RS  Morgan, GJ  Hemminki, K 
Citation: Weinhold N, etal., Nat Genet. 2013 May;45(5):522-5. doi: 10.1038/ng.2583. Epub 2013 Mar 17.
Pubmed: (View Article at PubMed) PMID:23502783
DOI: Full-text: DOI:10.1038/ng.2583

A number of specific chromosomal abnormalities define the subgroups of multiple myeloma. In a meta-analysis of two genome-wide association studies of multiple myeloma including a total of 1,661 affected individuals, we investigated risk for developing a specific tumor karyotype. The t(11;14)(q13;q32) translocation in which CCND1 is placed under the control of the immunoglobulin heavy chain enhancer was strongly associated with the CCND1 c.870G>A polymorphism (P = 7.96 x 10(-11)). These results provide a model in which a constitutive genetic factor is associated with risk of a specific chromosomal translocation.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 11353784
Created: 2016-07-21
Species: All species
Last Modified: 2016-07-21
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.